Avicanna Inc (AVCN) - Total Assets
Based on the latest financial reports, Avicanna Inc (AVCN) holds total assets worth CA$22.08 Million CAD (≈ $15.97 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore AVCN cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Avicanna Inc - Total Assets Trend (2016–2025)
This chart illustrates how Avicanna Inc's total assets have evolved over time, based on quarterly financial data. See AVCN net asset value for net asset value and shareholders' equity analysis.
Avicanna Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Avicanna Inc's total assets of CA$22.08 Million consist of 37.2% current assets and 62.8% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 1.3% |
| Accounts Receivable | CA$3.55 Million | 16.7% |
| Inventory | CA$3.85 Million | 18.1% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$626.43K | 3.0% |
| Goodwill | CA$334.00K | 1.6% |
Asset Composition Trend (2016–2025)
This chart illustrates how Avicanna Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Avicanna Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Avicanna Inc's current assets represent 37.2% of total assets in 2025, a decrease from 99.9% in 2016.
- Cash Position: Cash and equivalents constituted 1.3% of total assets in 2025, down from 98.3% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 18.1% of total assets.
Avicanna Inc Competitors by Total Assets
Key competitors of Avicanna Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
|
China | CN¥6.49 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Celltrion Pharm Inc
KQ:068760
|
Korea | ₩745.80 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
China | CN¥11.80 Billion |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940
|
China | CN¥3.12 Billion |
Avicanna Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.96 | 0.85 | 0.50 |
| Quick Ratio | 0.49 | 0.37 | 0.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-321.27K | CA$-1.30 Million | CA$-5.44 Million |
Avicanna Inc - Advanced Valuation Insights
This section examines the relationship between Avicanna Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.90 |
| Latest Market Cap to Assets Ratio | 0.54 |
| Asset Growth Rate (YoY) | 5.6% |
| Total Assets | CA$21.24 Million |
| Market Capitalization | $11.37 Million USD |
Valuation Analysis
Below Book Valuation: The market values Avicanna Inc's assets below their book value (0.54x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Avicanna Inc's assets grew by 5.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Avicanna Inc (2016–2025)
The table below shows the annual total assets of Avicanna Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CA$21.24 Million ≈ $15.37 Million |
+5.60% |
| 2024-12-31 | CA$20.12 Million ≈ $14.55 Million |
-8.44% |
| 2023-12-31 | CA$21.97 Million ≈ $15.89 Million |
+24.70% |
| 2022-12-31 | CA$17.62 Million ≈ $12.75 Million |
-21.00% |
| 2021-12-31 | CA$22.30 Million ≈ $16.13 Million |
-26.04% |
| 2020-12-31 | CA$30.16 Million ≈ $21.81 Million |
-33.23% |
| 2019-12-31 | CA$45.16 Million ≈ $32.67 Million |
+60.27% |
| 2018-12-31 | CA$28.18 Million ≈ $20.39 Million |
+1230.88% |
| 2017-12-31 | CA$2.12 Million ≈ $1.53 Million |
+2176.82% |
| 2016-12-31 | CA$93.00K ≈ $67.28K |
-- |
About Avicanna Inc
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios … Read more